DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $882,492 | +3.4% | 3,557 | 0.0% | 0.34% | +8.9% |
| Q2 2023 | $853,680 | -4.8% | 3,557 | 0.0% | 0.32% | -12.0% |
| Q1 2023 | $896,506 | -6.1% | 3,557 | -1.1% | 0.36% | -13.1% |
| Q4 2022 | $954,716 | +1.3% | 3,597 | -1.4% | 0.41% | -3.7% |
| Q3 2022 | $942,000 | +1.2% | 3,647 | -0.7% | 0.43% | +10.0% |
| Q2 2022 | $931,000 | -13.6% | 3,672 | 0.0% | 0.39% | +8.4% |
| Q1 2022 | $1,077,000 | -10.8% | 3,672 | 0.0% | 0.36% | +0.6% |
| Q4 2021 | $1,208,000 | +3.2% | 3,672 | -4.4% | 0.36% | -7.5% |
| Q3 2021 | $1,170,000 | +16.2% | 3,842 | +2.4% | 0.39% | +15.9% |
| Q2 2021 | $1,007,000 | +19.2% | 3,752 | 0.0% | 0.33% | +9.9% |
| Q1 2021 | $845,000 | +1.4% | 3,752 | 0.0% | 0.30% | -6.2% |
| Q4 2020 | $833,000 | +3.0% | 3,752 | -0.2% | 0.32% | -3.3% |
| Q3 2020 | $809,000 | +21.7% | 3,758 | 0.0% | 0.33% | +12.8% |
| Q2 2020 | $665,000 | +27.9% | 3,758 | 0.0% | 0.30% | +0.7% |
| Q1 2020 | $520,000 | -9.9% | 3,758 | 0.0% | 0.29% | +19.0% |
| Q4 2019 | $577,000 | +6.3% | 3,758 | 0.0% | 0.25% | -2.4% |
| Q3 2019 | $543,000 | +1.9% | 3,758 | +0.8% | 0.25% | +4.5% |
| Q2 2019 | $533,000 | +8.3% | 3,730 | 0.0% | 0.24% | +2.5% |
| Q1 2019 | $492,000 | +27.8% | 3,730 | 0.0% | 0.24% | +12.4% |
| Q4 2018 | $385,000 | -7.9% | 3,730 | -3.1% | 0.21% | +11.7% |
| Q3 2018 | $418,000 | +10.0% | 3,850 | 0.0% | 0.19% | +1.6% |
| Q2 2018 | $380,000 | +0.8% | 3,850 | 0.0% | 0.18% | -0.5% |
| Q1 2018 | $377,000 | +5.6% | 3,850 | 0.0% | 0.19% | +6.3% |
| Q4 2017 | $357,000 | +8.2% | 3,850 | 0.0% | 0.18% | +1.7% |
| Q3 2017 | $330,000 | +1.5% | 3,850 | 0.0% | 0.17% | 0.0% |
| Q2 2017 | $325,000 | -1.2% | 3,850 | 0.0% | 0.17% | +3.0% |
| Q1 2017 | $329,000 | +9.7% | 3,850 | 0.0% | 0.17% | -37.2% |
| Q4 2016 | $300,000 | -0.7% | 3,850 | 0.0% | 0.27% | -11.9% |
| Q3 2016 | $302,000 | -22.4% | 3,850 | 0.0% | 0.30% | -23.0% |
| Q2 2016 | $389,000 | +6.6% | 3,850 | 0.0% | 0.39% | +12.6% |
| Q1 2016 | $365,000 | +2.0% | 3,850 | 0.0% | 0.35% | -2.0% |
| Q4 2015 | $358,000 | +9.1% | 3,850 | 0.0% | 0.36% | +2.9% |
| Q3 2015 | $328,000 | -0.6% | 3,850 | 0.0% | 0.34% | +2.4% |
| Q2 2015 | $330,000 | +0.9% | 3,850 | 0.0% | 0.34% | +1.5% |
| Q1 2015 | $327,000 | -0.6% | 3,850 | 0.0% | 0.33% | -1.2% |
| Q4 2014 | $329,000 | – | 3,850 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |